Duke-UNC Collaborative Pediatric Clinical Pharmacology Postdoctoral Training Program

摘要 杜克大学和北卡罗来纳大学教堂山分校(UNC)在过去的9年里 在成人和儿科临床药理学方面成功的T32博士后培训计划 卓越的研究环境，在儿科药物发现、药物开发、 药代动力学/药效学和药物安全性。这项新的申请旨在获得持续的资金 儿科临床药理学培训方案部分的儿科职位。对 儿科临床药师很高，我们在培养临床医生方面有着出色的记录- 科学家，包括儿科医生，以满足这一领域日益增长的劳动力需求。我们有一个非常好的和 应聘者种类繁多，符合条件的应聘者比有资金支持的职位多得多。此新应用程序 描述了我们为期两年的培训计划(3名实习生/年)，该计划在国际上提供强大的领导力- 来自多个学科的积极参与儿科临床药理学的公认导师，a 广泛的尖端技术和资源，以及独特的协作环境 制度保障。该项目的国家申请者主要来自儿科医学博士。 寻求儿科临床药理学职业道路的医学专业培训计划，也来自 药学高级临床/转化性研究培训。学员，以个性化发展为导向 计划和指导团队，完成儿科临床药理学课程并参与计划- 为获得当代儿科临床药理学研究各方面的专门知识而开展的具体活动 为成功的学术、监管或行业职业生涯做好准备，成为未来的领导者和导师 一代代儿科临床药剂师。经验丰富的教师导师是根据他们的 在构成本培训计划核心的四个重点领域中至少一个领域的研究效率：药物 处置和行动；定量药理学/药物计量学和临床试验设计；个体化 治疗；药物引起的器官毒性。这一儿科培训计划的新组成部分包括 更加注重精确配药、使用真实数据和药物计量学；扩大试点计划 专门和创新领域的儿科临床药理学培训，包括怀孕和哺乳； 增强职业发展机会；并扩大与其他T32计划的合作。一个 这一培训项目的独特之处在于儿科药物计量学培训的力度。浓厚的兴趣 在我们的实习生人才库中，对儿科临床的投资是无与伦比的 杜克大学和北卡罗来纳大学的药理学研究资源，智力丰富的生物医学科学环境 研究三角园区和我们长期优秀的研究和培训基础设施相结合，创造了 一个无与伦比的机会，在儿科临床药理学培训。

ABSTRACT Duke University and the University of North Carolina at Chapel Hill (UNC) have had, for the past 9 years, a successful T32 postdoctoral training program in adult and pediatric clinical pharmacology that builds on our exceptional research environment with world-class programs in pediatric drug discovery, drug development, pharmacokinetics/ pharmacodynamics, and drug safety. This new application aims to secure continued funding of pediatric positions for the pediatric clinical pharmacology training program component. The demand for pediatric clinical pharmacologists is high, and we have an outstanding track record of training clinician- scientists, including pediatricians, to meet the growing workforce needs in this field. We have an excellent and diverse applicant pool with many more qualified applicants than funded positions. This new application describes our 2-year training program (3 trainees/year), which offers strong leadership, internationally- recognized mentors from multiple disciplines who are actively involved in pediatric clinical pharmacology, a wide-array of cutting edge technologies and resources, and a uniquely collaborative environment with strong institutional support. The national applicant pool for this program is derived primarily from MDs in pediatric medical specialty training programs seeking a career path in pediatric clinical pharmacology, and also from PharmDs in advanced clinical/translational research training. Trainees, guided by individualized development plans and mentoring teams, complete pediatric clinical pharmacology coursework and engage in program- specific activities to gain expertise in all aspects of contemporary pediatric clinical pharmacology research in preparation for successful academic, regulatory or industrial careers as leaders and mentors to future generations of pediatric clinical pharmacologists. Experienced faculty mentors are chosen based on their research productivity in at least one of four focus areas that form the core of this training program: Drug Disposition and Action; Quantitative Pharmacology/Pharmacometrics & Clinical Trial Design; Individualized Therapy; Drug-induced Organ Toxicity. Novel components of this pediatric training program include an increased focus on precision dosing, use of real-world data, and pharmacometrics; pilot programs to expand pediatric clinical pharmacology training in specialty and innovative areas including pregnancy and lactation; enhanced professional development opportunities; and expansion of collaborations with other T32 programs. A unique feature of this training program is the strength in pediatric pharmacometrics training. The keen interest in pediatric clinical pharmacology within our trainee pool, the unparalleled investment in pediatric clinical pharmacology research resources at Duke and UNC, the intellectually-rich biomedical science environment of Research Triangle Park, and our longstanding excellent research and training infrastructure combine to create a moment of unsurpassed opportunity for training in pediatric clinical pharmacology.